Kimberly Lynn Blackwell, MD

Adjunct Professor in the Department of Medicine
Campus mail Duke Box 3893, Durham, NC 27710
Phone (919) 668-1748
Email address black034@mc.duke.edu

Breast cancer angiogenesis
Breast cancer in younger women
Hormonal therapy
Neoadjurant therapy for breast cancer

Current Clinical Investigations

Principal Investigator, A Phase I-II Study of Neoadjuvant Evacet/Paclitaxel/Hyperthermia in Locally Advanced Breast Cancer Patients.

Investigator, Development of Screening Markers for Breast Cancer using Circulating Immune Complexes: Collaborative Study with Diagen Medical Technologies.

Principal Investigator, Use of Plasma D-Dimer as a Predictive Marker in Colorectal Carcinoma: Correlative Science Study with Genentech, Inc.

Principal Investigator, A randomized, Phase II study of gabapentin or glutamine to prevent the peripheral neuropathy/myalgia associated with weekly taxol administration in metastatic breast and lung cancer.

Investigator, A Phase 2, Randomized, Double-Masked, Multicenter Study of Two Dose Levels of ERA-923 for the treatment of Metastatic Breast Cancer in Postmenopausal Women who have failed Tamoxifen therapy. Genetics Institute.

Investigator, A Phase I Study of Combined Doxil/Hyperthermia in Stage IV Breast Cancer.

Education and Training

  • Fellow in Hematology-Oncology, Medicine, Duke University, 1997 - 2000
  • Medical Resident, Medicine, Duke University, 1994 - 1997
  • M.D., Mayo School of Health Sciences, 1994

Publications

Hamilton, Erika P., and Kimberly L. Blackwell. “How can we optimize treatment of HER2-positive metastatic breast cancer?.” Oncology (Williston Park) 27, no. 3 (March 2013): 180–82.

PMID
23687786
Scholars@Duke

Blackwell, K. L. “An option after pertuzumab and TDM-1.” Oncology Report, no. AUG (January 1, 2013).

Scholars@Duke

Cristofanilli, Massimo, Stephen R. D. Johnston, Alexey Manikhas, Henry L. Gomez, Oleg Gladkov, Zhimin Shao, Sufia Safina, et al. “A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer..” Breast Cancer Res Treat 137, no. 2 (January 2013): 471–82. https://doi.org/10.1007/s10549-012-2369-x.

PMID
23239151
Full Text

Hamilton, E., K. Blackwell, A. C. Hobeika, T. M. Clay, G. Broadwater, X. R. Ren, W. Chen, et al. “Correction: phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion..” J Transl Med, 2013. https://doi.org/10.1186/1479-5876-11-82.

PMID
23536971
Full Text

Cristofanilli, M., S. R. D. Johnston, A. Manikhas, H. L. Gomez, O. Gladkov, Z. Shao, S. Safina, et al. “A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer.” Breast Cancer Research and Treatment 137, no. 2 (2013): 471–82. https://doi.org/10.1007/s10549-012-2369-x.

Full Text

Verma, Sunil, David Miles, Luca Gianni, Ian E. Krop, Manfred Welslau, José Baselga, Mark Pegram, et al. “Trastuzumab emtansine for HER2-positive advanced breast cancer..” N Engl J Med 367, no. 19 (November 8, 2012): 1783–91. https://doi.org/10.1056/NEJMoa1209124.

PMID
23020162
Full Text

Roe, Matthew T., Paul W. Armstrong, Keith A. A. Fox, Harvey D. White, Dorairaj Prabhakaran, Shaun G. Goodman, Jan H. Cornel, et al. “Prasugrel versus clopidogrel for acute coronary syndromes without revascularization..” N Engl J Med 367, no. 14 (October 4, 2012): 1297–1309. https://doi.org/10.1056/NEJMoa1205512.

PMID
22920930
Full Text

Blackwell, Kimberly L., Harold J. Burstein, Anna Maria Storniolo, Hope S. Rugo, George Sledge, Gursel Aktan, Catherine Ellis, et al. “Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study..” J Clin Oncol 30, no. 21 (July 20, 2012): 2585–92. https://doi.org/10.1200/JCO.2011.35.6725.

PMID
22689807
Full Text

Ren, Xiu-Rong, Junping Wei, Gangjun Lei, Jiangbo Wang, Jiuyi Lu, Wenle Xia, Neil Spector, et al. “Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cells..” Breast Cancer Res 14, no. 3 (June 7, 2012). https://doi.org/10.1186/bcr3204.

PMID
22676470
Full Text

Betof, A. S., Z. N. Rabbani, M. E. Hardee, S. J. Kim, G. Broadwater, R. C. Bentley, S. A. Snyder, et al. “Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification..” Br J Cancer 106, no. 5 (February 28, 2012): 916–22. https://doi.org/10.1038/bjc.2012.32.

PMID
22333602
Full Text

Pages